Interleukin-6 receptor subunit alpha (IL-6R) mRNA (IL-6R mRNA)

Interleukin-6 receptor subunit alpha (IL-6R) mRNA is the messenger RNA transcript that encodes the alpha subunit of the receptor for interleukin-6 (IL-6), a key pro-inflammatory cytokine (UniProt: P08887). This mRNA is a therapeutic target for nucleic acid-based drugs, such as antisense oligonucleotides (ASOs), which aim to reduce the production of both membrane-bound and soluble IL-6R protein (PubMed: 29109662). By decreasing the availability of the receptor, these therapies inhibit both classic signaling (via membrane-bound IL-6R) and trans-signaling (via soluble IL-6R), the latter of which is often associated with chronic inflammatory pathologies (PubMed: 22517865). Dysregulation of the IL-6 pathway is implicated in numerous autoimmune and inflammatory diseases, including rheumatoid arthritis and various systemic inflammatory syndromes (PubMed: 28545701). Targeting the mRNA provides a mechanism to lower systemic receptor levels, potentially offering a more durable or comprehensive anti-inflammatory effect compared to protein-targeting monoclonal antibodies (Ionis Pharmaceuticals). This approach allows for the modulation of the IL-6 pathway at the pre-translational level, which can be particularly effective in managing conditions characterized by high ligand concentrations. Clinical development of drugs targeting this mRNA has focused on optimizing delivery and minimizing off-target effects common to oligonucleotide therapies. Overall, IL-6R mRNA represents a strategic target for precision medicine in immunology.

Other names

IL6R mRNACD126 mRNAgp80 mRNAInterleukin-6 receptor mRNA

Antisense oligonucleotide-mediated degradation of mRNA via RNase H recruitment, leading to reduced expression of both membrane-bound and soluble IL-6 receptor proteins.